In addition, ADAR1 dependent RNA editing of GLI1 led to resistance of myeloma cells to chemotherapeutic drug lenalidomide treatment [42], suggesting that inhibition of GLI1 editing could enhance the cell sensitivity to drug treatment. Here, GLI1 is linked to plasma cell myeloma.